Our News

[dmpro_breadcrumbs bc_home_icon=”on” bc_home_color=”#FFFFFF” bc_separator_icon=”E||divi||400″ bc_schema=”on” bc_separator_color=”#FFFFFF” bc_separator_space=”3px” bc_item_padding=”|||0px|false|false” admin_label=”Breabcrumbs – Do Not Edit” _builder_version=”4.18.0″ _module_preset=”default” items_text_color=”#FFFFFF” hover_text_color=”gcid-e72a664e-1e92-42ff-861c-cca5b6954cae” active_text_color=”gcid-e72a664e-1e92-42ff-861c-cca5b6954cae” module_alignment=”left” custom_margin=”0px||0px|-10px|true|false” custom_padding=”0px|0px|0px|0px|true|true” locked=”off” global_colors_info=”{%22gcid-e72a664e-1e92-42ff-861c-cca5b6954cae%22:%91%22bc_hover_home_color%22,%22active_text_color%22,%22hover_text_color%22%93}”][/dmpro_breadcrumbs]

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.

Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.

Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.

Yourgene Health logo
Prev Next
17 November 2023 – Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

17 November 2023 – Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

Yourgene’s LightBench instrument offers precise and accurate target enrichment of PacBio HiFi SMRTbell sequencing libraries increasing HiFi sequencing yields

Manchester, UK, 16 November 2023: Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, and PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration to optimise size selection for long-read sequencing workflows. PacBio has qualified Yourgene’s LightBench® instrument for the size selection of long DNA fragments, enabling high yields for HiFi sequencing data.

read more
17 November 2023 – Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

9 November 2023 – Yourgene Health and Laboriad Launch Non-invasive Prenatal Testing in Morocco

Yourgene Health installs first NIPT platform, the IONA test, in Morrocco, enabling Laboriad to offer safe, fast and accurate prenatal testing to expectant parents

Manchester, UK, and Rabat, MOROCCO, 09 November 2023: Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, has installed the first non-invasive prenatal testing (NIPT) workflow in Morocco based on the IONA® test at the Centre de Biologie Riad (Laboriad). By offering this service locally, Laboriad can broaden its offering and provide pregnant women fast, reliable results that reduce the need for invasive tests and the associated stress and anxiety for expectant parents.

read more
17 November 2023 – Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

7 November 2023 -IVDR certification achieved for DPYD genotyping assay – First product of its kind to conform with new IVDR requirements

IVDR certification achieved for DPYD genotyping assay

First product of its kind to conform with new IVDR requirements

Yourgene Health (part of the Novacyt group), an international specialist in clinical diagnostics, confirms – IVDR accreditation under the new requirements of the In Vitro Diagnostic Regulation (“IVDR”) for its DPYD genotyping assay, which helps identify cancer patients at risk of suffering a severe, and potentially life-threatening, reaction to common chemotherapy.

read more
17 November 2023 – Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

5 September 2023 – Yourgene Health Launches MagBench Automated DNA Extraction Instrument and Kit for NIPT Workflows

Yourgene Health Launches MagBench Automated DNA Extraction Instrument and Kit for NIPT Workflows

Offers clinical labs in APAC and Middle East cost-efficient, bench-top robotic cell-free DNA extraction workstation and reagents for Yourgene’s Sage 32 NIPT Workflow

Manchester, UK, and SINGAPORE, 5 September 2023: Yourgene Health plc (“Yourgene”, AIM: YGEN), a leading international molecular diagnostics group, today launched the Yourgene® MagBench™ Automated DNA Extraction Instrument and Kit.

read more
17 November 2023 – Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

25 January 2023 – Directorate Change

Andy Leeser is one of the UK’s most experienced mid-market corporate transformation specialists. He has been involved with a range of transformation projects and transactions, including refinancings and equity/ asset sales across the Automotive, Oil and Gas, Brewing, Retail and Telecommunications sectors.

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

16 August 2022 – Open Day and advance notice of AGM

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Open Day and advance notice of AGM Manchester, UK – 16 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be hosting an Open Day at its new facilities on Manchester...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

27 July 2022 – Audited Final Results

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Audited Final Results    Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its final results for the financial year ended 31 March...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

27 July 2022 – Dr John Brown CBE confirmed as Chairman

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Dr John Brown CBE confirmed as Chairman Manchester, UK – 27 July 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, confirms the appointment of Dr John Brown CBE as Chairman...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

26 April 2022 – Full year trading update

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Full year trading update Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides the following unaudited trading update for the year ended 31...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

26 April 2022 – Directorate Change

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate Change Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that after a five-year tenure, Adam Reynolds will step down from...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

06 April 2022 – Capital Markets Day

Yourgene Health plc (“Yourgene”  or the “Company”) Capital Markets Day Manchester, UK – 6 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be holding a Capital Markets Day for investors on Tuesday 26 April...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

17 February 2022 – Successful CTDA desktop review

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Successful CTDA desktop review Approval for sale of Clarigene® SARS-CoV-2 Test in the UK Manchester, UK - 17 February 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group,...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

25 January 2022 – Directorate Change

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate Change Manchester, UK - 25 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces the appointment of Mary Tavener as a Non-executive Director...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

19 January 2022 – Agreement of new debt facility

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Agreement of new debt facility Silicon Valley Bank facility to provide non-dilutive funding for accretive growth opportunities Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), a leading...

read more
25 Aug 2022 – Notice of AGM, Change of Registered Address and Investor Presentation

17 January 2022 – Current year trading update

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Current year trading update Further upgrade to full year revenue guidance following strong trading performance Manchester, UK – 17 January 2022: Yourgene (AIM: YGEN), the international molecular...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

14 December 2021 – Half-year Report

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) H1 revenues doubled year-on-yearFull year revenues to exceed already upgraded market expectations Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading integrated technologies and service...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

14 December 2021 – UKHSA contract award

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) UKHSA contract awardContract for the provision of the genetic sequencing services Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

18 November 2021 – DPYD screening recommended in Spain

Yourgene Health plc(“Yourgene” or the “Company”) DPYD screening recommended in SpainFollows recommendations in Germany, Wales, England and Belgium Manchester, UK – 18 November 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, welcomes...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

26 October 2021 – Half-year Trading update

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Trading updateImproved H1 and year-to-date performance supporting higher full-year expectations Manchester, UK – 26 October 2021: Yourgene (AIM: YGEN), a leading international molecular...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

28 September 2021 – AGM Statement Investor presentation

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) AGM StatementInvestor presentation Manchester, UK - 28 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, will be holding its Annual General Meeting (AGM)...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

1 September 2021 – Notice of AGM and Annual Report 2021

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Notice of AGM and Annual Report 2021Investor presentation Manchester, UK 1 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that the Notice of Annual...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

18 May 2021 – Launch of IONA® Care NIPT service offering

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Launch of IONA® Care NIPT service offeringExtended clinical menu to screen SCAs and AAs for pregnant women Manchester, UK – 18 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

29 April 2021 – Full year Trading update

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Full year Trading update10% year-on-year revenue growth Manchester, UK – 29 April 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

29 March 2021 – COVID-19 update

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) COVID-19 update Approved provider of day two and day eight coronavirus testing for international arrivals, for both PCR and sequencing Manchester, UK – 29 March 2021: Yourgene (AIM: YGEN), the...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

17 March 2021 – Appointment of VP of Sales North America

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Appointment of VP of Sales North AmericaStrategic hire to expand Yourgene’s commercial footprint in North America Manchester, UK – 17 March 2021: Yourgene (AIM: YGEN), the international molecular...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

22 February 2021 – Partnership with NPH

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Partnership with NPH To provide COVID-19 testing service for Leeds Bradford Airport Manchester, UK – 22 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

8 February 2021 – Trading update

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Trading update Strong H2 momentum expected to deliver double-digit annual growth but below expectations Deferred revenue opportunities, investment in offering and further new initiatives expected to...

read more
23 Dec 21 – DHSC contract awarded to support COVID-19 Winter surge testing

13 January 2021 – DPYD screening recommended in Belgium

Yourgene Health plc("Yourgene" or the "Group" or the "Company") DPYD screening recommended in Belgium Manchester, UK – 13 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the research article published on 11 January 2021, in...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

17 December 2020 – Half-year Report

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Report Manchester, UK – 17 December 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

2 December 2020 – DPYD kits recommended by NHS England

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) DPYD kits recommended by NHS England Manchester, UK – 2 December 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the Clinical Commissioning Urgent Policy Statement,...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

5 November 2020 – Directorate change

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Directorate changeChief Scientific Officer appointment to drive new product development roadmap Manchester, UK – 5 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group,...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

3 November 2020 – Partnership with Take2 Health Limited

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Partnership with Take2 Health LimitedYourgene to run genomic test for Nasopharyngeal Carcinoma (NPC) Screening in Taiwan Manchester, UK – 3 November 2020: Yourgene (AIM: YGEN), the international...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

26 October 2020 – Half-year Trading update

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Half-year Trading updateH1 year-on-year growth demonstrating the resilience of the Company Manchester, UK – 26 October 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group,...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

23 October 2020 – CQC registration

Yourgene Health plc(“Yourgene Health” or the "Company") CQC registration Manchester, UK – 23 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received notification from the Care Quality Commission...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

3 August 2020 – CE-IVD Mark for Clarigene™ SARS-CoV-2 test

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) CE-IVD Mark for Clarigene™ SARS-CoV-2 test Manchester, UK – 3 August 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has achieved CE-IVD marking for its...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

28 September 2020 – Launch of Yourgene Genomic Services

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Launch of Yourgene Genomic Services Manchester, UK – 28 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of Yourgene Genomic Services, an...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

24 September 2020 – DPD reimbursement in Germany

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) DPD reimbursement in Germany Manchester, UK – 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

22 September 2020 – AGM statement

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) AGM Statement Manchester, UK – 22 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be holding its Annual General Meeting (AGM) at 4:00pm today. At the meeting,...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

3 September 2020 – IONA® Nx Launch

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) IONA® Nx Launch Manchester, UK – 3 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA® Nx NIPT workflow, the Company’s new innovative...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

5 August 2020 – Result of Placing

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Result of Placing Manchester, UK – 5 August 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to confirm, further to the announcements made yesterday...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

28 July 2020 – Final Results

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Yourgene Health plc(“Yourgene”, the “Company” or the “Group”) Final Results Manchester, UK – 28 July 2020: Yourgene Health plc (AIM: YGEN), the international...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

30 June 2020 – COVID-19 assay launched

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) COVID-19 assay launched Launch of Clarigene™ SARS-CoV-2 test (‘RUO’) Manchester, UK – 30 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the launch of its...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

16 June 2020 – Collaboration in COVID-19 testing

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Collaboration in COVID-19 testing Supporting the effort to get Britain back to work Manchester, UK – 16 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

7 April 2020 – Presentation on ‘Adapting during crisis’

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Presentation on ‘Adapting during crisis’ Manchester, UK – 7 April 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that Hayden Jeffreys, Chief Operating...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

17 February 2020 – CE Marking Technical File submission

Yourgene Health plc(“Yourgene” or the “Company”) CE Marking Technical File submission Manchester, UK – 17 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has submitted its CE Marking Technical File for the...

read more
24 December 2020 – COVID-19 update: approved provider for UK Government and response to new virus strain

14 February 2020 – TGA approves DPYD for sale in Australia

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) TGA approves DPYD for sale in Australia Southern Cross, Yourgene’s Australian distributor, to sell the chemotoxicity diagnostic assay in the Territory Manchester, UK – 14 February 2020:Yourgene (AIM:...

read more
2 December 2019 – Half-year Report

2 December 2019 – Half-year Report

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.  Yourgene Health plc  (“Yourgene”, the “Company” or the “Group”)  Half-year Report  Manchester, UK – 2 December 2019: Yourgene Health plc (AIM:...

read more
2 December 2019 – Half-year Report

29 November 2019 – Bionow Double Award Wins

Yourgene Health plc (“Yourgene” or the “Group” or the “Company”) Bionow Double Award Wins Manchester, UK – 29 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won Bionow Investment Deal of Year and Bionow...

read more
2 December 2019 – Half-year Report

14 October 2019 – Half year trading update

Yourgene Health plc (“Yourgene” or the “Group”) Half year trading update Manchester, UK – 14 October 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides a positive trading update for the six months to 30 September 2019....

read more
2 December 2019 – Half-year Report

26 September 2019 – CE-IVD Certification renewal

CE-IVD Certification renewal Manchester, UK – 26 September 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that in preparation for a 2020 product launch and as a contingency for BREXIT, the Company has successfully...

read more
2 December 2019 – Half-year Report

20 August 2019 – Notice of AGM 

Yourgene Health plc (“Yourgene” or the “Company”) Notice of AGM Manchester, UK – 20 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Annual General Meeting (AGM) will be held at 4:00pm on 17 September 2019 at...

read more
2 December 2019 – Half-year Report

29 July 2019 – Appointment of Director

Yourgene Health plc (“Yourgene”, the “Company” or the “Group”) Appointment of Director Manchester, UK – 29 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the...

read more
2 December 2019 – Half-year Report

25 April 2019 – Completion of Acquisition

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY...

read more
2 December 2019 – Half-year Report

8 April 2019 – Full-year Trading Update

Yourgene Health plc (“Yourgene”, the “Company” or the “Group”) Full-year Trading Update Manchester, UK – 8 April 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a trading...

read more
3 December 2018 – Half-year Results

3 December 2018 – Half-year Results

Yourgene Health plc(“Yourgene”, the “Company” or the “Group”) Half-year Results Manchester, UK – 3 December 2018: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited...

read more
3 December 2018 – Half-year Results

12 October 2018 – Trading Update & Notice of Results

Premaitha Health plc(“Premaitha” or the “Group”) Trading Update & Notice of Results Manchester, UK – 12 October 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to provide an update on trading for the...

read more
3 December 2018 – Half-year Results

04 October 2018 – $1 million collaboration agreement

Premaitha Health PLC(“Premaitha,” the “Company” or the “Group”) $1 million collaboration agreementPartnership to provide genetic testing based on next generation sequencing for oncology Manchester, UK – 4 October 2018: Premaitha (AIM: NIPT), a leading international...

read more
3 December 2018 – Half-year Results

4 July 2018 – Board Changes

Premaitha Health plc(“Premaitha” or the “Group”) Board Changes Manchester, UK – 4 July 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Lyn Rees as Chief Executive Officer and Mr...

read more
3 December 2018 – Half-year Results

26 June 2018 – Collaboration with Abnova

Premaitha Health plc(“Premaitha” or the “Company”) Collaboration with Abnova Partnership to develop next generation sequencing capability for single cell analysis Manchester, UK – 26 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular...

read more
29 December 2017 – Half Year Results

29 December 2017 – Half Year Results

Premaitha Health PLC(“Premaitha”, the “Company” or the “Group”)Half year resultsManchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the...

read more
29 December 2017 – Half Year Results

21 November 2017 – Litigation First Instance Judgment

Premaitha Health plc(“Premaitha” or the “Company” or the “Group”) Litigation First Instance Judgment Manchester, UK – 21 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing...

read more
29 December 2017 – Half Year Results

13 October 2017 – Commercial progress in the Middle East

Premaitha Health PLC(“Premaitha” or the “Company”) Commercial progress in the Middle East Manchester, UK – 13 October 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces...

read more
29 December 2017 – Half Year Results

3 July 2017 – Litigation Update

Premaitha Health PLC(“Premaitha” or the “Company”) Litigation Update Manchester, UK – 3 July 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), provides the following update on...

read more
29 December 2017 – Half Year Results

5 June 2017 – India Business Update

Premaitha Health plc(“Premaitha” or the “Company” or the “Group”) India Business Update Manchester, UK – 5 June 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, is pleased to provide...

read more
29 December 2017 – Half Year Results

12 May 2017 – Update Re. Swiss Customer

Premaitha Health PLC(“Premaitha” or the “Company”) Update Re. Swiss Customer Manchester, UK – 12 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, announces that...

read more
29 December 2017 – Half Year Results

20 February 2017 – Middle East Business Update

Premaitha Health PLC(“Premaitha” or the “Company”) Middle East Business Update Manchester, UK – 20 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, is pleased to announce significant commercial...

read more
29 December 2017 – Half Year Results

15 February 2017 – Issue of Equity

Premaitha Health plc("Premaitha" or the "Company") Issue of Equity Manchester, UK - 15 February 2017: Premaitha Health plc (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces that it has agreed to issue to Harwood Capital...

read more
29 December 2017 – Half Year Results

7 February 2017 – Southern Europe Business Update

Premaitha Health PLC(“Premaitha” or the “Company”) Southern Europe Business Update Manchester, UK – 7 February 2017: Premaitha Health PLC (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces a number of new customers through...

read more
21 December 2016 – Half Year Results

21 December 2016 – Half Year Results

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 21 December 2016 Premaitha Health PLC (“Premaitha” or “the Company”) Half Year Results Manchester, UK – 21 December 2016: Premaitha Health (AIM: NIPT), developer of a leading CE-marked non-invasive...

read more
21 December 2016 – Half Year Results

27 October 2016 – AGM Statement

Issued on behalf of Premaitha Health plcManchester, UK: Thursday, 27 Oct 2016 Premaitha Health Plc(“Premaitha” or the “Company”) AGM Statement Manchester, UK – 27 October 2016 – At the Annual General Meeting of Premaitha to be held...

read more
21 December 2016 – Half Year Results

30 September 2016 – Annual Results 2016

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 30 Sept 2016 Premaitha Health plc(“Premaitha” or the “Company”) Final results Manchester, UK – 30 September 2016 - Premaitha Health plc (AIM: NIPT), developer of the...

read more
21 December 2016 – Half Year Results

22 April 2016 – Update on competitor patent litigation

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 22 April 2016 Premaitha Health plc(“Premaitha” or the “Company”)   Update on competitor patent litigation   Manchester, UK - 22 April 2016 - Premaitha Health PLC (AIM: NIPT, "Premaitha" or the...

read more
21 December 2016 – Half Year Results

20 April 2016 – Patent litigation rescheduled

Issued on behalf of Premaitha Health plc Manchester, UK: Wednesday, 20 April 2016 Premaitha Health plc(“Premaitha” or the “Company”) Patent litigation rescheduled Manchester, UK – 20 April 2016: Premaitha Health plc (AIM: NIPT), developer of the leading CE-marked...

read more
21 December 2016 – Half Year Results

26 January 2016 – Update on UK Litigation Timing

Issued on behalf of Premaitha Health plc Manchester, UK: Tuesday, 26 January 2016 Update on UK Litigation Timing Manchester, UK – 26 January 2016: Premaitha Health PLC (“Premaitha” or “the Company”; AIM: NIPT) provides investors with visibility of the timelines...

read more
21 December 2016 – Half Year Results

8 January 2016 – Update on competitor patent litigation

Manchester, UK – 8 January 2016 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal (NIPT) in vitro diagnostic kit, notes that Illumina, Inc. has today announced two patent...

read more
14 December 2015 – Results for the half year ended 30 September 2015

24 June 2015 – New IONA® test clinical data showcased

Issued on behalf of Premaitha Health plc Manchester, UK: Friday, 24 June 2015     New IONA® test clinical data showcased at the World Congress in Fetal Medicine Manchester, UK - 24 June 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM:...

read more
14 December 2015 – Results for the half year ended 30 September 2015

22 June 2015 – New contract for IONA® test

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 22 June 2015 New contract for IONA® test Manchester and Leeds, UK – 22 June 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA® test, the first CE-marked test...

read more
14 December 2015 – Results for the half year ended 30 September 2015

4 June 2015 – Directorate Change

Issued on behalf of Premaitha Health plc Manchester, UK: Thursday, 4 June 2015 Directorate Change Manchester, UK – 4 June 2015: Premaitha Health plc (“Premaitha” or “the Company”; AIM: NIPT) announces the appointment of Barry Hextall, CGMA, MBA, CertIOD as Chief...

read more
14 December 2015 – Results for the half year ended 30 September 2015

31 March 2015 – Centrum Badan DNA partners with Premaitha Health to offer the IONA® test in Poland

The two companies will work closely together as they establish Centrum Badan as Premaitha’s preferred partner laboratory within Poland.  

The IONA® test is the first CE-marked in vitro diagnostic (IVD) product for NIPT, enabling genetic laboratories such as Centrum Badan to offer NIPT in-house. It uses next-generation sequencing (NGS) technology to estimate the risk of a fetus having serious genetic disorders such as Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) and Patau’s syndrome (Trisomy 13) by analysing cell-free fetal DNA from a sample of maternal blood. The IONA test® has a higher detection rate and lower false positive rate than the current combined test available to pregnant women in Poland.  

read more
14 December 2015 – Results for the half year ended 30 September 2015

16 March 2015 – Notice of Patent Infringement Proceedings

Issued on behalf of Premaitha Health plc Manchester, UK: Monday, 16 March 2015 PRESS RELEASE Notice of Patent Infringement Proceedings Manchester, UK – 16 March 2015 – Premaitha Health plc (“Premaitha” AIM: NIPT) an innovative molecular diagnostics company employing...

read more

Our News

Yourgene have worked closely with Key Opinion Leaders, high profile partners, customers and market renowned experts within their chosen fields to develop a series of Your Expert papers. We aim to cover a range of different topics and content relevant to the portfolio of applications that Yourgene operates in. We aspire that these papers are relevant, informative, educational and add value.

Roll your mouse over the document to download.

Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice

Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs)that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population.

Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice

Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs)that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population.

Achieving cost savings in NIPT by enabling greater flexibility in blood collection tube choice

Non-invasive prenatal testing (NIPT) involves sequencing cell-free DNA (cfDNA) from maternal plasma to screen for fetal trisomy 21, 18, and 13, and in some instances other chromosomal abnormalities. Making NIPT routinely available has required the use of blood collection tubes (BCTs)that maintain the sample at ambient temperatures, whilst also retaining the integrity of the cell-free DNA (cfDNA) population.

Clinical Performance

This content can be added here or for more complex layouts link to a layout in the Divi Library by clicking on the ‘dynamic content’ icon top right in this editor window.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.

Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.

Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.

Resources

This content can be added here or for more complex layouts link to a layout in the Divi Library by clicking on the ‘dynamic content’ icon top right in this editor window.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.

Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer id nisi libero. Vivamus posuere velit at nunc blandit, in facilisis diam tincidunt. Maecenas porta sem enim, eget accumsan nulla pellentesque ac. Aenean venenatis tellus at mi ornare varius. Donec eget enim tempor, molestie elit et, mattis ipsum. Fusce fermentum, neque eget luctus commodo, sem nunc ornare metus, quis ornare velit erat vel massa.

Sed tristique enim nunc, eu imperdiet nulla venenatis varius. Morbi porttitor orci at arcu scelerisque, quis convallis lorem congue. Mauris eget tortor diam. Sed blandit erat arcu. Donec in risus maximus, commodo nibh vitae, laoreet magna. Duis hendrerit fermentum porttitor. Mauris rhoncus leo felis, et ultricies neque mollis a.